Welcome to our dedicated page for Ligand Pharma SEC filings (Ticker: LGNXZ), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Our SEC filing database is enhanced with expert analysis from Rhea-AI, providing insights into the potential impact of each filing on Ligand Pharma's stock performance. Each filing includes a concise AI-generated summary, sentiment and impact scores, and end-of-day stock performance data showing the actual market reaction. Navigate easily through different filing types including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, proxy statements (DEF 14A), and Form 4 insider trading disclosures.
Designed for fundamental investors and regulatory compliance professionals, our page simplifies access to critical SEC filings. By combining real-time EDGAR feed updates, Rhea-AI's analytical insights, and historical stock performance data, we provide comprehensive visibility into Ligand Pharma's regulatory disclosures and financial reporting.
LIGAND PHARMACEUTICALS INC director John L. Lamattina reported selling 4,591 shares of Common Stock on June 10, 2026 in a series of open-market transactions. The reported weighted-average sale prices ranged from about $246.63 to $251.90 per share across the different trades.
Individual transactions included sales such as 3,405 shares at a weighted-average price of $251.6158 and smaller blocks at prices around $247–$250 per share. Following these sales, he directly holds 26,969 shares of Ligand Pharmaceuticals Common Stock.
LGND filing a Form 144 notices proposed sales of common stock tied to equity awards. The excerpt lists a stock option exercise covering 4,000 shares with a trade date 06/12/2026, and two restricted stock items of 1,252 shares (06/06/2025) and 1,209 shares (06/05/2026).
The Form 144 entry records the securities type, dates, and the filer as an issuer-designated sale; cash/consideration method is listed as Cash.
Ligand Pharmaceuticals, Inc. Rule 144 notice: JALAA Equities LP reported a sale of 500 common shares on 06/10/2026 for $124,980.42. The filing also shows 4,500 common shares linked to Wells Fargo Clearing Services with an Open Market purchase date of 04/28/2005.
LIGAND PHARMACEUTICALS INC director Martine Zimmermann reported routine equity compensation and related tax withholding. She received 836 restricted stock units, each convertible into one share of common stock, granted by the board on June 5, 2026. These RSUs fully vest on the earlier of the next annual stockholder meeting or the first anniversary of the grant date. The company also granted her non-qualified stock options for 2,938 shares at an exercise price of $237.00 per share, with the same vesting schedule and expiration in 2036. To cover taxes on RSU settlement, 182 shares of common stock were withheld, a non-market disposition. After these transactions, she directly holds 5,279 common shares and 2,938 options.
Sabba Stephen L reported acquisition or exercise transactions in this Form 4 filing.
Ligand Pharmaceuticals director Stephen L. Sabba received new equity awards. On June 5, 2026, he was granted 836 restricted stock units, each representing one share of common stock, and 2,938 non-qualified stock options with a strike price of $237.00 per share.
Both the RSUs and options fully vest on the earlier of the company’s next annual stockholder meeting following the grant date or the first anniversary of the grant date. Following the stock grant, Sabba directly holds 33,629 shares of Ligand common stock, plus the newly granted options expiring on June 5, 2036.
LIGAND PHARMACEUTICALS INC director John L. Lamattina received equity awards from the board on June 5, 2026. He was granted 836 restricted stock units, each representing one share of common stock, increasing his direct common stock holdings to 31,560 shares.
He was also granted a Non-Qualified Stock Option for 2,938 shares of common stock at an exercise price of 237.0000 per share, expiring on June 5, 2036. Both the RSUs and the option award fully vest on the earlier of the next annual meeting of company stockholders following the grant date or the first anniversary of the grant date.
Ligand Pharmaceuticals director John W. Kozarich received new equity awards as part of his board compensation. On June 5, 2026, he was granted 836 restricted stock units, each representing one share of common stock, and a non-qualified stock option for 2,938 shares at an exercise price of $237.00 per share. Both awards fully vest on the earlier of the company’s next annual stockholder meeting following the grant date or the first anniversary of the grant date. Following these grants, Kozarich directly holds 42,622 shares of Ligand common stock.